Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -11,00k | 2,53M | Derivative Exercise and Sale | 229,85 | 24,91k | - |
| 2026-05-01 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | 14,25k | 0,00 | Derivative Exercise and Retained Stock | - | 24,91k | 133,73% |
| 2026-02-27 | Mr. Robert J. DeckerController & CAO | -4,08k | 538,72k | Derivative Exercise and Sale | 115,67 - 247,87 | 24,46k | - |
| 2026-02-20 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -1,32k | 324,76k | Verkauf | 245,66 | 26,24k | -4,80% |
| 2026-02-13 | Mr. James SwansonExec. VP & Chief Information Officer | 11,06k | 0,00 | Derivative Exercise and Retained Stock | - | 25,70k | 75,56% |
| 2026-02-13 | Mr. James SwansonExec. VP & Chief Information Officer | -62,08k | 4,91M | Derivative Exercise and Sale | 162,75 - 243,76 | 25,70k | - |
| 2026-02-13 | Mr. James SwansonExec. VP & Chief Information Officer | -4,21k | 1,03M | Sale to Issuer | 243,45 - 244,55 | 25,70k | -14,09% |
| 2026-02-13 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | 9,49k | 0,00 | Derivative Exercise and Retained Stock | - | 23,00k | 70,28% |
| 2026-02-15 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | -526,00 | 128,04k | Derivative Exercise and Sale | 243,39 - 243,45 | 23,00k | - |
| 2026-02-17 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | -5,94k | 1,45M | Verkauf | 243,39 | 23,00k | -20,53% |
| 2026-02-13 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | -4,14k | 1,01M | Sale to Issuer | 243,45 - 244,55 | 23,00k | -15,27% |
| 2026-02-13 | Mr. Joaquin DuatoCEO & Chairman | 48,48k | 0,00 | Derivative Exercise and Retained Stock | - | 356,30k | 15,75% |
| 2026-02-13 | Mr. Joaquin DuatoCEO & Chairman | -36,23k | 8,86M | Derivative Exercise and Sale | 243,45 - 244,55 | 356,30k | - |
| 2026-02-13 | Ms. Jennifer L. TaubertExec. VP & Worldwide Chairman of Innovative Medicine | 16,44k | 0,00 | Derivative Exercise and Retained Stock | - | 194,45k | 9,23% |
| 2026-02-13 | Ms. Jennifer L. TaubertExec. VP & Worldwide Chairman of Innovative Medicine | -15,72k | 3,84M | Derivative Exercise and Sale | 243,45 - 244,55 | 194,45k | - |
| 2026-02-13 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | 6,93k | 0,00 | Derivative Exercise and Retained Stock | - | 27,56k | 33,60% |
| 2026-02-18 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -22,62k | 2,79M | Derivative Exercise and Sale | 115,67 - 244,53 | 27,56k | - |
| 2026-02-13 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -2,29k | 558,78k | Sale to Issuer | 243,45 - 244,55 | 27,56k | -7,66% |
| 2026-02-13 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | 8,02k | 0,00 | Derivative Exercise and Retained Stock | - | 23,57k | 51,58% |
| 2026-02-13 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | -8,36k | 2,04M | Derivative Exercise and Sale | 243,45 - 244,55 | 23,57k | - |
| 2026-02-13 | Mr. Robert J. DeckerController & CAO | 2,68k | 0,00 | Derivative Exercise and Retained Stock | - | 24,46k | 12,31% |
| 2026-02-13 | Mr. Robert J. DeckerController & CAO | -1,06k | 257,79k | Derivative Exercise and Sale | 243,45 - 244,55 | 24,46k | - |
| 2026-02-15 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -54,84k | 5,22M | Derivative Exercise and Sale | 156,15 - 243,45 | 10,66k | - |
| 2026-02-13 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | 3,42k | 0,00 | Derivative Exercise and Retained Stock | - | 19,83k | 20,85% |
| 2026-02-13 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | -1,59k | 387,15k | Derivative Exercise and Sale | 243,45 - 244,55 | 19,83k | - |
| 2026-02-13 | Mr. Joseph James WolkExec. VP & CFO | -107,78k | 18,01M | Derivative Exercise and Sale | 115,67 - 244,55 | 85,01k | - |
| 2026-02-13 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | 8,33k | 0,00 | Derivative Exercise and Retained Stock | - | 114,66k | 7,84% |
| 2026-02-13 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | -7,27k | 1,78M | Derivative Exercise and Sale | 243,45 - 244,55 | 114,66k | - |
| 2026-02-06 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | 5,24k | 533,39k | Derivative Exercise and Retained Stock | 101,87 | 22,92k | 29,62% |
| 2026-02-06 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -10,34k | 1,43M | Derivative Exercise and Sale | 101,87 - 239,99 | 22,92k | - |
| 2026-02-06 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | 2,29k | 233,28k | Derivative Exercise and Retained Stock | 101,87 | 16,41k | 16,22% |
| 2026-02-06 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | -3,34k | 460,63k | Derivative Exercise and Sale | 101,87 - 239,99 | 16,41k | - |
| 2026-02-06 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | 11,68k | 1,19M | Derivative Exercise and Retained Stock | 101,87 | 106,32k | 12,34% |
| 2026-02-06 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | -27,27k | 3,77M | Derivative Exercise and Sale | 101,87 - 239,99 | 106,32k | - |
| 2026-02-05 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | 2,70k | 349,03k | Derivative Exercise and Retained Stock | 129,51 | 15,55k | 20,97% |
| 2026-02-05 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | -6,23k | 674,84k | Derivative Exercise and Sale | 129,51 - 237,90 | 15,55k | - |
| 2023-08-23 | Dr. Paula A. JohnsonIndependent Director | -11,00 | 0,00 | Sale to Issuer | - | 89,00 | -11,00% |
| 2026-01-26 | Mr. Joaquin DuatoCEO & Chairman | -100,00k | 22,12M | Verkauf | 220,99 - 221,48 | 307,81k | -24,52% |
| 2025-11-26 | Mr. John G. MorikisDirector | 1,25k | 257,69k | Kauf | 206,15 | 1,85k | 208,68% |
| 2025-10-17 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -21,72k | 755,61k | Derivative Exercise and Sale | 157,92 - 192,71 | 10,66k | - |
| 2025-09-04 | Ms. Jennifer L. TaubertExec. VP & Worldwide Chairman of Innovative Medicine | -56,47k | 4,29M | Derivative Exercise and Sale | 101,87 - 177,81 | 178,01k | - |
| 2025-08-29 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | 1,95k | 225,67k | Derivative Exercise and Retained Stock | 115,67 | 12,85k | 17,90% |
| 2025-08-29 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | -9,57k | 588,84k | Derivative Exercise and Sale | 115,67 - 177,20 | 12,85k | - |
| 2025-08-22 | Mr. Joaquin DuatoCEO & Chairman | -125,82k | 9,73M | Derivative Exercise and Sale | 101,87 - 179,21 | 407,79k | - |
| 2025-08-15 | Mr. Joseph James WolkExec. VP & CFO | -16,82k | 1,26M | Derivative Exercise and Sale | 101,87 - 176,91 | 84,98k | - |
| 2025-07-17 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -19,14k | 3,13M | Verkauf | 163,55 | 10,66k | -64,23% |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
